Illimis secures funding for GAIA-based Alzheimer’s therapeutics
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor…
Central Nervous System
-
-
Niagen Bioscience signs exclusive licence deal for PD therapy
Niagen Bioscience has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital, Bergen, Norway, for the development of…
-
Eli Lilly receives FDA approval for Amyvid label update
The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid…
-
Novartis concludes Regulus Therapeutics acquisition
Novartis has completed its previously announced acquisition of US-based biopharmaceutical company Regulus Therapeutics for $1.7bn, strengthening its renal disease portfolio.…
-
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for…
-
Draig secures $140m for neuropsychiatric disorder therapies
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies…
-
Supernus makes depression drug play with $795m Sage buyout
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals.…
-
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat…
-
Aytu BioPharma to commercialise Exxua for MDD in the US
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to…
-
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical…
